Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Inclusion Criteria

• •Disease Characteristics:
• •Patients with a documented histologic or cytologic diagnosis of a pancreatic malignancy
• •Performance Status: Patients with a Karnofsky performance status \> 70% (or equivalent, ECOG 0-1) and an expected survival rate of at least 3 months
• •Hematopoietic: Hemoglobin \> 10g/dL; WBC \> 3000 per mm3; Granulocyte count \> 1500 per mm3; platelet count \> 100,000 per mm3
• •Hepatic: Total bilirubin \< 1.5 times the institutional upper limit of normal (IULN); AST or ALT \< 2 X IULN
• •Renal: Creatinine \< IULN
• •Cardiovascular: Patients with LVEF \>/= 50% by required MUGA/2D-ECHO study
• •Pulmonary: Patients with DF and FEV1 \>/= 60 % by required Pulmonary Function Tests
• •Gastrointestinal:Patients with severe anorexia or other related symptomology are excluded
• •Central Nervous System: Patient with known metastatic disease to the CNS are excluded
• •Other: Patients who have had a prior imaging study with a murine antibody may be included. Patients agreeing to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.